1. Home
  2. GEVO vs ZNTL Comparison

GEVO vs ZNTL Comparison

Compare GEVO & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gevo Inc.

GEVO

Gevo Inc.

N/A

Current Price

$1.81

Market Cap

343.7M

Sector

Industrials

ML Signal

N/A

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

N/A

Current Price

$1.73

Market Cap

165.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GEVO
ZNTL
Founded
2005
2014
Country
United States
United States
Employees
N/A
106
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
343.7M
165.1M
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
GEVO
ZNTL
Price
$1.81
$1.73
Analyst Decision
Buy
Strong Buy
Analyst Count
4
11
Target Price
$5.11
★ $7.44
AVG Volume (30 Days)
★ 4.4M
1.4M
Earning Date
11-10-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 58.82
18.03
EPS
★ N/A
N/A
Revenue
★ $711,000.00
N/A
Revenue This Year
$29.71
N/A
Revenue Next Year
$2.42
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.09
$1.28
52 Week High
$2.97
$6.95

Technical Indicators

Market Signals
Indicator
GEVO
ZNTL
Relative Strength Index (RSI) 72.13 33.46
Support Level $1.62 $1.63
Resistance Level $1.91 $2.76
Average True Range (ATR) 0.12 0.17
MACD 0.08 0.02
Stochastic Oscillator 71.49 19.47

Price Performance

Historical Comparison
GEVO
ZNTL

About GEVO Gevo Inc.

Gevo Inc is a growth-oriented company that focuses on hard to decarbonize market sectors such as jet fuel, certain specialty fuels, on-road fuels, chemicals and materials, and certain products for the food chain such as protein and feeds made as co-products from its processes. It produces and sells competitively priced, renewable, drop-in products for these sectors, and generate carbon abatement value through its plant design and business systems. It owns and operates an ethanol plant with an adjacent CCS facility, Class VI carbon-storage well, and others. The group is currently developing the world's first large-scale ATJ facility to be co-located at the North Dakota site.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: